Post-Marketing Safety Study of Ramucirumab Plus FOLFIRI: Analysis of Age and Initial Dose of Irinotecan in Patients with Metastatic Colorectal Cancer
Abstract Background There is limited real-world evidence regarding the safety of ramucirumab plus FOLFIRI in patients with metastatic colorectal cancer (mCRC). Objective We evaluated the safety of ramucirumab plus FOLFIRI in patients with mCRC by age and initial dose of irinotecan. Patients and Meth...
Main Authors: | Toshiki Masuishi, Soshi Nagaoka, Long Jin, Kenichi Yoshizawa |
---|---|
Format: | Article |
Language: | English |
Published: |
Adis, Springer Healthcare
2023-04-01
|
Series: | Drugs - Real World Outcomes |
Online Access: | https://doi.org/10.1007/s40801-023-00366-2 |
Similar Items
-
Therapeutic response to ramucirumab + folfiri in patients with metastatic gastric cancer
by: Hamid Rezvani, et al.
Published: (2022-01-01) -
Irinotecan plus folinic acid/continuous 5-fluorouracil as simplified bimonthly FOLFIRI regimen for first-line therapy of metastatic colorectal cancer
by: Höhler Thomas, et al.
Published: (2004-07-01) -
Safety and Effectiveness of Aflibercept + Fluorouracil, Leucovorin, and Irinotecan (FOLFIRI) for the Treatment of Patients with Metastatic Colorectal Cancer (mCRC) in Current Clinical Practice: OZONE Study
by: Ian Chau, et al.
Published: (2020-03-01) -
Impact of prior chemotherapy with two different fluoropyrimidines on the efficacy of capecitabine plus irinotecan or FOLFIRI with or without bevacizumab in metastatic colorectal cancer: a post hoc analysis of the AXEPT study
by: Satoru Iwasa, et al.
Published: (2023-04-01) -
Cetuximab plus Irinotecan as third line chemotherapy for metastatic colorectal cancer
by: Moe, M, et al.
Published: (2008)